Close menu

October 21st, 2021 | 12:17 CEST

Sartorius, Defence Therapeutics, QIAGEN - Still long potential

  • Biotechnology
Photo credits:

Since the outbreak of the Corona pandemic, biotech and pharmaceutical shares have been among the top performers on the stock market. In addition to vaccine producers such as BioNTech and Pfizer, the share price of the US pharmaceutical Company Moderna also multiplied. Other winners included diagnostics companies and laboratory equipment suppliers, process technology specialists and manufacturers of biopharmaceuticals. Biopharmaceuticals promise enormous growth potential even after Corona, especially the market such as gene and cell therapies is growing dynamically at the moment.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: SARTORIUS AG O.N. | DE0007165607 , DEFENCE THERAPEUTICS INC | CA24463V1013 , QIAGEN NV EO -_01 | NL0012169213

Table of contents:

    Defence Therapeutics - The next success story

    Due to the daily flood of information in the media regarding SARS-CoV-2, since the spring of 2020, society has forgotten that other disease patterns are significantly more dangerous and can lead to death more quickly. In 2019, the Federal Statistical Office counted 239,591 deaths nationwide due to cancer and other neoplasms. Cancer was thus the second most common cause of death, accounting for nearly one in four deaths that year. Only cardiovascular disease has killed more people in Germany each year.

    Through its Accum platform technology, the Canadian biotechnology Company Defence Therapeutics has positioned itself broadly. The therapeutic process is used both in the fight against cancer and in developing vaccines against infectious diseases such as Covid-19. ADC drug development serves as the basis. Antibody-drug conjugates promise great potential in cancer therapy because they can specifically destroy cancer cells. The therapeutic window of ADCs, that is, the ratio of efficacy to safety, compares favorably with other forms of therapy. Because the technology is highly specific, acting directly on the cancer cell, side effects can be reduced. The novel Accum method enables precise transport of vaccine antigens or antibody-drug conjugates in the intact form to target cells, which is expected to improve efficiency and efficacy.

    Convincing results were published by Defence Therapeutics last week regarding an in vitro study. Defence successfully selected and tested 5 AccumTM variants for ADC therapy with T-deruxtecan. The 5 Accum-T-deruxtecan combinations selected enhance the efficacy of ADC therapy with T-deruxtecan by approximately fivefold in the trastuzumab- and T-DM1-resistant HER2 positive breast cancer cell line model called JIMT-1. At a 0.001 ug/ml concentration, T-deruxtecan induces only about 13% cytotoxicity compared with the 5 Accum T-deruxtecan variants, which increase cytotoxicity by 21-37%.

    Defence Therapeutics CEO Sebastien Plouffe said in a statement: "The good results have confirmed the expectations of our scientific team that the AccumTM can enhance the transport of T-deruxtecan to the nucleus and consequently significantly increased the efficacy of the ADC. It also confirms and reiterates the strength and optimization of our AccumTM platform in therapeutic ADCs against cancer and the substantial competitive advantage we have with our AccumTM variants based on our AccumTM technology platform."

    The stock market value of the Company, which is traded in Toronto and Frankfurt, is currently EUR 153 million. Thus, the Company still offers significant potential due to its broad range of applications. However, as is usual with biotechnology companies, investors should also accept the risk of a setback.

    Sartorius - Outlook "only" confirmed

    Despite excellent nine-month figures and confirmation of the outlook, the shares of DAX newcomer Sartorius lost around 4% in value at the start of trading; in the course of trading, the value of the preference shares stabilized and were only down around 1.5%. In the nine months to the end of September, sales revenue rose 50% to EUR 2.53 billion. Adjusted earnings before interest, taxes, depreciation and amortization increased by 77% to EUR 866 million, resulting in an adjusted EBITDA margin of 34.3%, compared with 29.1% in the previous year.

    At the same time, the laboratory equipment supplier almost doubled its profit by 93% to an adjusted EUR 406 million. For the year as a whole, the Göttingen-based Company anticipates a 45% increase in revenues with an EBITDA margin of 34%.

    In 2025, the sales revenue sound barrier of EUR 5 billion is expected to fall; the target operating margin will then be 32%, according to management. In addition to equipping pharmaceutical and research laboratories, Sartorius, which could profit twice from the corona pandemic by manufacturing biopharmaceuticals, including corona vaccines, also sees rapid growth in other application areas. According to Sartorius CEO Joachim Kreuzburg, the development of biopharmaceuticals such as gene and cell therapies is currently growing very dynamically.

    QIAGEN declares war on tuberculosis

    In the fight against tuberculosis, QIAGEN is setting an example with the market launch and successful CE marking of the novel tuberculosis test QIAreach QuantiFERON-TB for regions with a high disease burden. The new test is expected to contribute to the global fight against TB by improving access to reliable and straightforward TB testing, particularly in resource-poor countries with a high disease burden.

    QIAreach QuantiFERON-TB is a milestone in the fight against a pathogen estimated to be carried by more than two billion people worldwide. The test is based on proven QuantiFERON-TB Gold Plus technology. It runs on a portable device that enables highly sensitive, digital detection of TB infection as part of a simple and cost-effective complete workflow, improving access to reliable interferon-gamma release assay (IGRA) testing.

    Clinical evaluation of the test showed a high level of concordance and increased sensitivity compared to QuantiFERON-TB Gold Plus, QIAGEN's gold standard IGRA test-marketed worldwide. QIAGEN shares jumped above resistance at EUR 45, generating a buy signal.

    Research to combat a wide range of diseases continues apace, even after Corona. Sartorius is likely to benefit significantly in the future from the development of biopharmaceuticals such as gene and cell therapies, while QIAGEN is declaring war on tuberculosis by launching a new test. Defence Therapeutics' novel Accum technology applies to various diseases and promises long-term potential.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

    New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

    • Biotechnology
    • Pharma
    • Healthcare

    Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.


    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.


    Commented by Armin Schulz on November 29th, 2023 | 06:30 CET

    MorphoSys, Cardiol Therapeutics, Bayer - Where will the rebound start first?

    • Biotechnology
    • Pharma

    2023 was a challenging year for pharmaceutical and biotech companies. After the boom years of the Corona pandemic, many companies went into a tailspin. But not just vaccine manufacturers were hit; others were dragged down too. The markets are currently volatile. MorphoSys has seen a peak gain of 145% since the beginning of the year - but is currently only up 35%. Cardiol Therapeutics has also gained over 140% and has recently consolidated. The share is currently up 74% since the beginning of the year. Only Bayer's performance curve is pointing downwards. The share is currently worth 34% less than on January 2. We look at where the rebound will start first after the consolidations.